Abstract |
Refractory acute myeloid leukemia (AML) remains an incurable malignancy despite the clinical use of novel targeted therapies, new antibody-based therapies, and cellular therapeutics. Here, we describe the preclinical development of a novel cell therapy that targets the antigen CLEC12A with a biparatopic bridging protein. Bridging proteins are designed as "CAR-T cell engagers," with a CAR-targeted protein fused to antigen binding domains derived from antibodies. Here, we created a CD19-anti-CLEC12A bridging protein that binds to CAR19 T cells and to the antigen CLEC12A. Biparatopic targeting increases the potency of bridging protein-mediated cytotoxicity by CAR19 T cells. Using CAR19 T cells that secrete the bridging protein we demonstrate potent activity against aggressive leukemic cell lines in vivo This CAR-engager platform is facile and modular, as illustrated by activity of a dual- antigen bridging protein targeting CLEC12A and CD33, designed to counter tumor heterogeneity and antigen escape, and created without the need for extensive CAR T-cell genetic engineering. CAR19 T cells provide an optimal cell therapy platform with well-understood inherent persistence and fitness characteristics.
|
Authors | Paul D Rennert, Fay J Dufort, Lihe Su, Tom Sanford, Alyssa Birt, Lan Wu, Roy R Lobb, Christine Ambrose |
Journal | Molecular cancer therapeutics
(Mol Cancer Ther)
Vol. 20
Issue 10
Pg. 2071-2081
(10 2021)
ISSN: 1538-8514 [Electronic] United States |
PMID | 34253594
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | ©2021 The Authors; Published by the American Association for Cancer Research. |
Chemical References |
- Antigens, CD19
- CD33 protein, human
- CLEC12A protein, human
- Lectins, C-Type
- Receptors, Mitogen
- Sialic Acid Binding Ig-like Lectin 3
|
Topics |
- Animals
- Antigenic Drift and Shift
- Antigens, CD19
(immunology)
- Apoptosis
- Cell Proliferation
- Cytotoxicity, Immunologic
(immunology)
- Humans
- Immunotherapy
(methods)
- Immunotherapy, Adoptive
(methods)
- In Vitro Techniques
- Lectins, C-Type
(immunology)
- Leukemia, Myeloid, Acute
(drug therapy, immunology, metabolism, pathology)
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Receptors, Mitogen
(immunology)
- Sialic Acid Binding Ig-like Lectin 3
(immunology)
- T-Lymphocytes
(immunology)
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
|